CD274 and non-small cell lung carcinoma: Besides playing a central role as a critical factor in current immunotherapy regimens, PD-L1 has also been demonstrated in several studies to emerge as a potential prognostic biomarker that can predict which individuals with NSCLC were more responsive to ICIs [139–144].